Literature DB >> 35290637

Qualitative and Quantitative Analysis of DNA Cytidine Deaminase Activity.

Rachel DeWeerd1, Abby M Green2,3.   

Abstract

The human genome encodes eleven DNA cytidine deaminases in the AID/APOBEC family, which encompass endogenous roles ranging from genetic diversification of the immunoglobulin locus to virus restriction. All AID/APOBEC functions are enabled by their catalyzation of cytidine deamination resulting in mutations and DNA damage. When acting aberrantly, deaminases can cause off-target mutations in the cellular genome resulting in somatic mutations, DNA damage, and genome instability. An association between cytidine deaminase-induced mutations and human cancers has been recognized over the last decade, necessitating assays for investigation of intracellular deaminase activity. Here we present two assays for deamination activity which enable in vitro evaluation of in vivo events. We define both a qualitative assay to confirm deaminase activity within cells as well as a quantitative assay for granular evaluation and comparisons of deamination activity across different cell populations or experimental conditions. The two procedures are customizable assays which can easily be adapted to individual labs and experiments.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AID; APOBEC; Cytidine deaminase; DNA base editors; Deaminase

Mesh:

Substances:

Year:  2022        PMID: 35290637     DOI: 10.1007/978-1-0716-2063-2_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

1.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

3.  APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

Authors:  Brandon Leonard; Steven N Hart; Michael B Burns; Michael A Carpenter; Nuri A Temiz; Anurag Rathore; Rachel I Vogel; Jason B Nikas; Emily K Law; William L Brown; Ying Li; Yuji Zhang; Matthew J Maurer; Ann L Oberg; Julie M Cunningham; Viji Shridhar; Debra A Bell; Craig April; David Bentley; Marina Bibikova; R Keira Cheetham; Jian-Bing Fan; Russell Grocock; Sean Humphray; Zoya Kingsbury; John Peden; Jeremy Chien; Elizabeth M Swisher; Lynn C Hartmann; Kimberly R Kalli; Ellen L Goode; Hugues Sicotte; Scott H Kaufmann; Reuben S Harris
Journal:  Cancer Res       Date:  2013-10-23       Impact factor: 12.701

Review 4.  Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity.

Authors:  Rafael Casellas; Uttiya Basu; William T Yewdell; Jayanta Chaudhuri; Davide F Robbiani; Javier M Di Noia
Journal:  Nat Rev Immunol       Date:  2016-02-22       Impact factor: 53.106

Review 5.  Activation-induced cytidine deaminase links class switch recombination and somatic hypermutation.

Authors:  Ilmi Okazaki; Kiyotsugu Yoshikawa; Kazou Kinoshita; Masamichi Muramatsu; Hitoshi Nagaoka; Tasaku Honjo
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

6.  APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Authors:  Hui Chen; Caroline E Lilley; Qin Yu; Darwin V Lee; Jody Chou; Iñigo Narvaiza; Nathaniel R Landau; Matthew D Weitzman
Journal:  Curr Biol       Date:  2006-03-07       Impact factor: 10.834

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  Mutational processes molding the genomes of 21 breast cancers.

Authors:  Serena Nik-Zainal; Ludmil B Alexandrov; David C Wedge; Peter Van Loo; Christopher D Greenman; Keiran Raine; David Jones; Jonathan Hinton; John Marshall; Lucy A Stebbings; Andrew Menzies; Sancha Martin; Kenric Leung; Lina Chen; Catherine Leroy; Manasa Ramakrishna; Richard Rance; King Wai Lau; Laura J Mudie; Ignacio Varela; David J McBride; Graham R Bignell; Susanna L Cooke; Adam Shlien; John Gamble; Ian Whitmore; Mark Maddison; Patrick S Tarpey; Helen R Davies; Elli Papaemmanuil; Philip J Stephens; Stuart McLaren; Adam P Butler; Jon W Teague; Göran Jönsson; Judy E Garber; Daniel Silver; Penelope Miron; Aquila Fatima; Sandrine Boyault; Anita Langerød; Andrew Tutt; John W M Martens; Samuel A J R Aparicio; Åke Borg; Anne Vincent Salomon; Gilles Thomas; Anne-Lise Børresen-Dale; Andrea L Richardson; Michael S Neuberger; P Andrew Futreal; Peter J Campbell; Michael R Stratton
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

9.  DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.

Authors:  Benjamin Jm Taylor; Serena Nik-Zainal; Yee Ling Wu; Lucy A Stebbings; Keiran Raine; Peter J Campbell; Cristina Rada; Michael R Stratton; Michael S Neuberger
Journal:  Elife       Date:  2013-04-16       Impact factor: 8.140

10.  Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase.

Authors:  Iñigo Narvaiza; Daniel C Linfesty; Benjamin N Greener; Yoshiyuki Hakata; David J Pintel; Eric Logue; Nathaniel R Landau; Matthew D Weitzman
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.